Edesa Biotech, Inc. announced significant findings from its Phase 3 clinical trial of paridiprubart (EB05), a promising treatment for Acute Respiratory Distress Syndrome (ARDS), which was...
Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company based in Toronto, has reported promising results from its Phase 3 clinical trial for the drug candidate...
